AAPL 190.415 0.3663% MSFT 422.65 -0.1016% GOOG 175.36 0.8512% GOOGL 174.14 0.9449% AMZN 185.71 -0.1505% NVDA 943.46 -0.3001% META 473.555 -1.6582% TSLA 174.87 0.5058% TSM 154.06 -0.977% LLY 776.1758 -1.3779% V 280.145 -0.2972% AVGO 1436.4972 0.0228% JPM 204.205 1.0366% UNH 522.225 0.9033% NVO 133.03 -1.2105% WMT 63.485 6.109% LVMUY 170.79 -0.2511% XOM 117.87 -0.5988% LVMHF 855.728 -0.1473% MA 461.6867 0.805%

Pieris Pharmaceuticals Inc

Healthcare US PIRS


Last update at 2024-05-16T16:46:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -33.27700M -45.73800M -37.06600M -25.46900M -27.06600M
Minority interest - - - - -
Net income -31.25300M -43.36600M -37.23000M -23.75500M -26.75400M
Selling general administrative 16.39M 16.59M 16.71M 18.44M 18.44M
Selling and marketing expenses - - - - -
Gross profit 25.90M 31.42M 29.32M 46.28M 29.10M
Reconciled depreciation 2.78M 2.37M 2.13M 1.04M 0.57M
Ebit -43.47400M -51.83100M -33.92100M -27.15700M -30.83100M
Ebitda -35.30100M -48.14600M -31.79400M -26.11700M -30.26100M
Depreciation and amortization 8.17M 3.69M 2.13M 1.04M 0.57M
Non operating income net other - 2.40M -3.65600M -0.02600M 1.80M
Operating income -43.47400M -51.83100M -33.92100M -27.15700M -30.83100M
Other operating expenses 61.20M 79.56M 63.24M 73.44M 59.93M
Interest expense -10.19700M 6.09M 3.15M 1.69M 3.77M
Tax provision - 0.00000M 0.16M 0.00000M -0.31200M
Interest income 0.72M 0.00400M 0.51M 1.71M 1.96M
Net interest income 0.72M 0.00400M 0.51M 1.71M 1.96M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.02400M -2.37200M 0.16M -1.71400M -0.31200M
Total revenue 25.90M 31.42M 29.32M 46.28M 29.10M
Total operating expenses 61.20M 79.56M 63.24M 73.44M 59.93M
Cost of revenue - - - - 0.00000M
Total other income expense net 10.20M 6.09M -3.14500M 1.69M 3.77M
Discontinued operations - - - - -
Net income from continuing ops -33.27700M -45.73800M -37.23000M -25.46900M -26.75400M
Net income applicable to common shares - -45.73800M -37.23000M -28.29900M -26.75400M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 95.49M 153.56M 105.01M 141.10M 141.34M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.45M 6.55M 3.58M 4.07M 4.57M
Total liab 67.56M 102.81M 73.98M 89.75M 101.41M
Total stockholder equity 27.93M 50.76M 31.03M 51.35M 39.94M
Deferred long term liab - - - - 53.30M
Other current liab 10.75M 15.79M 5.48M 4.96M 9.11M
Common stock 0.07M 0.07M 0.06M 0.06M 0.05M
Capital stock 0.07M 0.07M 0.06M 0.06M 0.05M
Retained earnings -290.42100M -257.14400M -211.40600M -174.17600M -147.06600M
Other liab 18.73M 38.40M 35.91M 47.26M 53.33M
Good will - - - - -
Other assets - 2.90M 7.24M 3.15M 0.91M
Cash 38.63M 117.76M 70.44M 62.26M 74.87M
Cash and equivalents - - - - -
Total current liabilities 36.58M 50.56M 22.14M 27.00M 48.08M
Current deferred revenue 20.82M 25.12M 12.63M 11.26M 35.61M
Net debt -25.53200M -103.92300M -53.47400M -46.04300M -74.86700M
Short term debt 0.86M 1.05M 1.03M 0.73M -
Short long term debt - - - - -
Short long term debt total 13.10M 13.84M 16.96M 16.22M -
Other stockholder equity 318.53M 307.00M 242.67M 227.47M 189.93M
Property plant equipment 20.70M 23.03M 25.98M 19.50M 5.05M
Total current assets 73.42M 127.62M 75.72M 115.01M 135.38M
Long term investments - - - - 0.00000M
Net tangible assets 27.93M 50.76M 31.03M 51.35M 39.94M
Short term investments 20.53M 0.00000M 0.00000M 41.89M 53.24M
Net receivables 5.81M 3.31M 1.71M 6.79M 2.70M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.15M 8.61M 3.01M 10.05M 3.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.25400M 0.83M -0.29500M -1.99500M -2.98200M
Additional paid in capital - - - - -
Common stock total equity - 0.07M 0.06M 0.06M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - -257.14400M -211.40600M -174.17600M -147.06600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.37M 2.90M 3.31M 3.15M 0.91M
Deferred long term asset charges - - - - -
Non current assets total 22.07M 25.93M 29.29M 26.08M 5.96M
Capital lease obligations 13.10M 14.89M 16.96M 16.22M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -21.23600M -0.94900M 41.94M 12.30M -7.17700M
Change to liabilities - 36.48M -18.85000M -28.18100M 13.32M
Total cashflows from investing activities - -0.94900M 39.21M 9.84M -8.87500M
Net borrowings - - - - -
Total cash from financing activities 7.21M 59.13M 10.12M 32.17M 48.51M
Change to operating activities - 5.73M -2.87000M -0.79900M -0.69000M
Net income -33.27700M -45.73800M -37.23000M -25.46900M -26.75400M
Change in cash -79.12900M 47.33M 8.18M -12.60700M 36.99M
Begin period cash flow 117.76M 70.44M 62.26M 74.87M 37.88M
End period cash flow 38.63M 117.76M 70.44M 62.26M 74.87M
Total cash from operating activities -59.93200M -7.66000M -45.89600M -52.46700M -1.06600M
Issuance of capital stock 6.92M 57.10M 9.62M 31.00M 47.21M
Depreciation 2.78M 2.37M 2.13M 1.04M 0.57M
Other cashflows from investing activities - - - 12.30M -7.17700M
Dividends paid - - - - -
Change to inventory - 5.73M -2.87000M -0.79900M -
Change to account receivables -2.62400M -1.81300M 5.34M -4.05500M 12.51M
Sale purchase of stock - 59.13M 10.12M 32.21M 48.51M
Other cashflows from financing activities 0.29M 2.03M 0.49M 1.17M 1.30M
Change to netincome - 5.18M 5.40M 4.08M 3.23M
Capital expenditures 1.04M 0.95M 2.73M 2.46M 1.70M
Change receivables - -1.81300M 5.34M -4.05500M 12.51M
Cash flows other operating - -4.23300M -1.39900M 0.52M -3.93900M
Exchange rate changes - - - - -1.58100M
Cash and cash equivalents changes - 50.52M 3.43M -10.46300M 36.99M
Change in working capital -33.37000M 30.52M -16.37700M -32.12100M 21.89M
Stock based compensation 4.40M 5.21M 5.09M 5.37M 4.94M
Other non cash items -0.46700M -0.03000M 0.33M -0.06900M -1.55400M
Free cash flow -60.97300M -8.60900M -48.62200M -54.92900M -2.76400M


  • Previous Close 11.37
  • Market Cap15.58M
  • Volume3644
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-19.20400M
  • Revenue TTM47.36M
  • Revenue Per Share TTM0.56
  • Gross Profit TTM -27.08000M
  • Diluted EPS TTM-0.34

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Pieris Pharmaceuticals Inc
-0.17 1.50% 11.20 - - 0.32 0.49 0.59 1.42
Novo Nordisk A/S
-1.63 1.21% 133.03 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
0.57 0.43% 132.69 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
1.20 0.27% 438.69 30.40 24.75 10.68 6.25 9.52 20.36
1.03 1.09% 96.00 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Pieris Pharmaceuticals Inc

255 State Street, Boston, MA, United States, 02109

Key Executives

Name Title Year Born
Mr. Stephen S. Yoder J.D. CEO, Pres & Director 1976
Dr. Hitto Kaufmann Ph.D. Sr. VP & Chief Scientific Officer 1971
Mr. Thomas Bures Sr. VP & CFO 1974
Maria Kelman Exec. Director of Investor Relations NA
Mr. Ahmed S. Mousa J.D. Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec. 1985
Mr. Frank Vollmering VP of HR NA
Dr. Christine Rothe Ph.D. VP and Head of Early Stage Project Leadership & Data Science NA
Dr. Shane Olwill Ph.D. Sr. VP & Chief Devel. Officer 1976
Mr. Prompong Chaikul Chief Supply Chain Officer 1987
Dr. Gordon Otto M.D., Ph.D. Head of Clinical Devel. Oncology NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).